Home
/
Adaptive Biotechnologies Corp
/
Financials
/
Quarterly
Adaptive Biotechnologies Corp — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Adaptive Biotechnologies Corp filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$93.97M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$58.88M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$52.44M
May 1, 2025
Q3
2025
Sep 30, 2024
$46.44M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$43.19M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$41.87M
May 1, 2025
Q3
2024
Sep 30, 2023
$37.92M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$48.93M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$37.65M
May 7, 2024
Q3
2023
Sep 30, 2022
$47.83M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$43.66M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$38.62M
May 3, 2023
Q3
2022
Sep 30, 2021
$39.47M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$38.51M
Aug 3, 2022
Q1
2022
Mar 31, 2021
$38.44M
May 4, 2022
Q3
2021
Sep 30, 2020
$26.30M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$20.99M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$20.91M
May 5, 2021
Q3
2020
Sep 30, 2019
$26.06M
Nov 10, 2020
Q2
2020
Jun 30, 2019
$22.14M
Aug 10, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$9.55M
Nov 5, 2025
Q2
2025
Jun 30, 2025
($25.61M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($29.85M)
May 1, 2025
Q3
2025
Sep 30, 2024
($32.07M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($46.22M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($47.51M)
May 1, 2025
Q3
2024
Sep 30, 2023
($50.30M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($47.81M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($57.70M)
May 7, 2024
Q3
2023
Sep 30, 2022
($45.28M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($52.05M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($62.74M)
May 3, 2023
Q3
2022
Sep 30, 2021
($55.90M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($49.30M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($40.64M)
May 4, 2022
Q3
2021
Sep 30, 2020
($36.72M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($33.54M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($31.40M)
May 5, 2021
Q3
2020
Sep 30, 2019
($13.95M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($15.66M)
Aug 10, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$10.29M
Nov 5, 2025
Q2
2025
Jun 30, 2025
($25.04M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($29.60M)
May 1, 2025
Q3
2025
Sep 30, 2024
($32.63M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($47.32M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($48.76M)
May 1, 2025
Q3
2024
Sep 30, 2023
($50.96M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($47.82M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($57.19M)
May 7, 2024
Q3
2023
Sep 30, 2022
($45.43M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($52.50M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($63.07M)
May 3, 2023
Q3
2022
Sep 30, 2021
($56.33M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($49.77M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($41.28M)
May 4, 2022
Q3
2021
Sep 30, 2020
($37.05M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($36.91M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($34.62M)
May 5, 2021
Q3
2020
Sep 30, 2019
($18.05M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($16.11M)
Aug 10, 2020